Valuation: SIGA Technologies, Inc.

Market Cap 234M 210M 194M 176M 333M 21.96B 342M 2.32B 924M 11.77B 879M 860M 37.2B P/E 2026 *
65.2x
P/E 2027 * 3.02x
Enterprise Value 116M 104M 96.03M 87.21M 165M 10.89B 170M 1.15B 458M 5.84B 436M 427M 18.45B EV / Sales 2026 *
1.94x
EV / Sales 2027 * 0.53x
Free-Float
57.27%
Yield 2026 *
18.4%
Yield 2027 * 18.4%
1 day-3.53%
1 week+2.09%
Current month+4.44%
1 month+0.47%
3 months+8.36%
6 months-30.22%
Current year-48.04%
1 week 2.95
Extreme 2.95
3.54
1 month 2.9
Extreme 2.9
3.54
Current year 2.83
Extreme 2.83
7.1
1 year 2.83
Extreme 2.83
7.1
3 years 2.83
Extreme 2.83
12.83
5 years 2.83
Extreme 2.83
26.99
10 years 2.25
Extreme 2.25
26.99
Manager TitleAgeSince
Chief Executive Officer 54 27/01/2024
Director of Finance/CFO 55 10/02/2011
Chief Operating Officer - 01/01/2020
Director TitleAgeSince
Director/Board Member 73 11/03/2009
Director/Board Member 72 16/06/2020
Director/Board Member 42 10/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
3/25/26 A Exercice

General Counsel

17,366 0.0243%
3/13/26 A Exercice

General Counsel

121,769 0.1700%
3/13/26 A Exercice

Chief Technology Officer

81,787 0.1142%
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%+2.09%-51.23%-35.60% 234M
+0.62%+0.77%+46.92%+137.61% 1,258B
-0.21%+5.82%+49.49%+91.27% 679B
+0.22%+2.61%+34.18%+111.75% 518B
+0.17%+2.76%+44.07%+69.71% 390B
-1.51%+1.30%+68.93%+44.54% 367B
+0.76%+2.27%+31.59%+60.36% 307B
-1.29%+0.90%+5.77%+37.60% 293B
-0.37%+0.28%+42.91%+73.04% 252B
+0.28%+1.07%+43.27%+122.96% 210B
Average -0.44%+1.14%+31.59%+71.32% 427B
Weighted average by Cap. +0.05%+1.18%+43.07%+96.00%

Financials

2026 *2027 *
Net sales 59.86M 53.69M 49.48M 44.93M 85.04M 5.61B 87.41M 592M 236M 3.01B 225M 220M 9.51B 162M 145M 134M 122M 230M 15.19B 237M 1.6B 639M 8.14B 608M 595M 25.73B
Net income 3.72M 3.34M 3.07M 2.79M 5.28M 349M 5.43M 36.81M 14.67M 187M 13.96M 13.66M 591M 77.88M 69.85M 64.37M 58.46M 111M 7.3B 114M 771M 307M 3.91B 292M 286M 12.37B
Net Debt -118M -106M -97.56M -88.6M -168M -11.07B -172M -1.17B -465M -5.93B -443M -434M -18.74B -148M -133M -122M -111M -210M -13.87B -216M -1.46B -583M -7.43B -555M -543M -23.49B
Projected Income Statement - Annual - SIGA Technologies, Inc.
Logo SIGA Technologies, Inc.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Employees
49
Date Price Change Volume
10/11/26 $3.175 -2.61% 419,417
09/11/26 $3.260 +5.16% 544,249
06/11/26 $3.100 +4.38% 330,844
05/11/26 $2.970 -5.71% 419,786
04/11/26 $3.150 +1.29% 313,412
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - SIGA Technologies, Inc.

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SIGA Technologies, Inc.
  1. Stock Market
  2. Stocks
  3. SIGA Stock